Table 2 Applied treatment options during disease progression in all patients (n = 35)
| Â | Therapies prior to initial PRRT | Additional therapies after initial PRRT and prior to salvage PRRT | Additional therapies after salvage PRRT |
|---|---|---|---|
Surgery | 23 (65.7%) | 9 (25.7%) | – |
Biotherapy | 22 (62.9%) | 5 (14.3%) | – |
Local ablative therapy (RFA, TACE, SIRT)a | 12 (34.3%) | 9 (25.7%) | 3 (8.6%) |
Chemotherapy | 2 (5.7%) | 1 (2.9%) | 7 (20.0%) |
Everolimus | – | 1 (2.9%) | 10 (28.6%) |
Protein Kinase Inhibitor / Antibodyb | – | – | 8 (22.9%) |
Radiotherapy | 2 (5.7%) | 3 (8.6%) | 1 (2.9%) |
Bone targeted therapyc | 7 (20.0%) | 5 (14.3%) | 4 (11.4%) |